1,721,269 research outputs found
ARE WE DOING OUR BEST TO PREVENT THE (UNEXPECTED) DISAPPOINTING SIDE EFFECTS OF AN OTHERWISE SUCCESSFUL CANCER TREATMENT?
No full textMitochondrial caseinolytic protease p: A possible novel prognostic marker and therapeutic target in cancer
Full text linkCaseinolytic protease P (ClpP) is a mitochondrial serine protease. In mammalian cells, the heterodimerization of ClpP and its AAA+ ClpX chaperone results in a complex called ClpXP, which has a relevant role in protein homeostasis and in maintaining mitochondrial functionality through the degradation of mitochondrial misfolded or damaged proteins. Recent studies demonstrate that ClpP is upregulated in primary and metastatic human tumors, supports tumor cell proliferation, and its overexpression desensitizes cells to cisplatin. Interestingly, small modulators of ClpP activity, both activators and inhibitors, are able to impair oxidative phosphorylation in cancer cells and to induce apoptosis. This review provides an overview of the role of ClpP in regulating mitochondrial functionality, in supporting tumor cell proliferation and cisplatin resistance; finally, we discuss whether this protease could represent a new prognostic marker and therapeutic target for the treatment of cancer
Citologia urinaria: risposta di una nuova variante della metodica di allestimento su strato sottile
No full textOncocytic Meningioma: histologica, molecular analysis and long term follow-up analysis of five cases
No full textSurgical resection versus radiofrequency ablation for the curative treatment of intrahepatic recurrent hepatocellular carcinoma: an unsolved question
No full textSystematic reviews and meta-analysis in stone disease: is this what we need to get stronger evidence?
No full textHodgkin Reed-Sternberg-Like Cells in Non-Hodgkin Lymphoma
Full text linkReed–Sternberg cells (RSCs) are hallmarks of classic Hodgkin lymphoma (cHL). However,
cells with a similar morphology and immunophenotype, so-called Reed–Sternberg-like cells (RSLCs),
are occasionally seen in both B cell and T cell non-Hodgkin Lymphomas (NHLs). In NHLs, RSLCs are
usually present as scattered elements or in small clusters, and the typical background microenviroment
of cHL is usually absent. Nevertheless, in NHLs, the phenotype of RSLCs is very similar to typical
RSCs, staining positive for CD30 and EBV, and often for B cell lineage markers, and negative
for CD45/LCA. Due to different therapeutic approaches and prognostication, it is mandatory to
distinguish between cHL and NHLs. Herein, NHL types in which RSLCs can be detected along with
clinicopathological correlation are described. Moreover, the main helpful clues in the differential
diagnosis with cHL are summarized
- …
